• linkedin
  • Increase Font
  • Sharebar

    Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drug


    Phase II RCC study to test immunotherapy combinations

    A new nationwide, multi-site phase II study of renal cell carcinoma, called FRACTION-RCC, will test whether combining nivolumab with other investigational immunotherapy agents is more effective than the commonly used drug combination of nivolumab plus ipilimumab. Patients over age 18 years who have been diagnosed with renal cell carcinoma that has metastasized can be considered potential candidates for the study.


    Phase II data for nonmuscle-invasive bladder Ca agent released

    Cold Genesys Inc. has reported interim clinical data from a phase II trial evaluating, an oncolytic virotherapy to treat patients with BCG-unresponsive nonmuscle-invasive bladder cancer. A total of 45 of the 67 enrolled patients had evaluable 6-month data in the ongoing clinical trial. Overall 6-month complete response (CR) was 46.7%. The carcinoma in situ (CIS) only group contained 14 CRs (58.3%), the CIS with Ta or T1 group contained four CRs (33.3%) and the Ta/T1 group contained three CRs (33.3%). CG0070 is designed to replicate inside tumor cells, causing cell lysis and immunogenic cell death. The ruptured cancer cells can also release tumor-derived antigens. Long-term follow-up data will be provided near the end of 2017, according to Cold Genesys.

    Ben Schwartz
    Ben Schwartz is Associate Editor, Contemporary OB/GYN.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available